AL

Almirall SAMAD Almirall Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Oct, 2024

Last price

Market cap $B

2.044

Small

Exchange

XMAD - Bolsa de Madrid

ALM.MC Stock Analysis

AL

Uncovered

Almirall SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

17/100

Low score

Market cap $B

2.044

Dividend yield

1.93 %

Shares outstanding

181.51 B

Almirall SA is a global biopharmaceutical company, which is focused on skin health. The company is headquartered in Barcelona, Barcelona and currently employs 1,846 full-time employees. The company went IPO on 2007-04-19. The firm focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The firm's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The firm operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

View Section: Eyestock Rating